Literature DB >> 14514343

Is [18F]-2-fluoro-2-deoxy-d-glucose (FDG) scintigraphy with non-dedicated positron emission tomography useful in the diagnostic management of suspected metastatic thyroid carcinoma in patients with no detectable radioiodine uptake?

Francesco Giammarile1, Zakia Hafdi, Claire Bournaud, Marc Janier, Claire Houzard, Claude Desuzinges, Roland Itti, Genevieve Sassolas, Francoise Borson-Chazot.   

Abstract

OBJECTIVE: Dedifferentiation of thyroid cancer leads to an inability of thyroid cells to concentrate iodine. In these cases, imaging methods that allow an accurate detection of recurrence and/or metastases at an early stage are essential for an adequate management of patients. Positron emission tomography using [18F]-2-fluoro-2-deoxy-d-glucose and a dedicated (dPET-FDG) or non-dedicated (nPET-FDG) camera has been suggested as a potential tool for the detection of tumour foci. DESIGN AND METHODS: This prospective study was undertaken to evaluate nPET-FDG in 51 consecutive patients (18 men, 33 women) with differentiated thyroid cancer (33 papillary, 11 follicular, four insular and three oncocytic (Hurthle-cell) thyroid carcinomas). Selection criteria were high thyroglobulin (Tg) levels (>10 ng/ml off-levothyroxine treatment) and no detectable radioiodine uptake, on a whole body scan performed with a high dose, in the absence of iodine contamination.
RESULTS: Results were interpreted in terms of assumed presence of tumoral tIssue. Sensitivity of nPET-FDG was similar to that of conventional imaging modalities (67%). False negative nPET-FDG (n=16) were observed mostly in cases of micro-lesions (lymph nodes or lung metastases). Conversely, nPET-FDG identified new tumoral sites in 11 cases. Better sensitivity was found for nPET-FDG in patients with Tg levels higher than 15 microg/l (P<0.05). On a patient basis, results of nPET-FDG were equivalent to that of dPET-FDG. Finally, nPET-FDG changed treatment strategy in seven patients.
CONCLUSIONS: nPET-FDG has a high sensitivity for the detection of tumour sites in patients when pathological iodine uptake cannot be demonstrated and appears to be a useful method in patients with elevated Tg levels, especially when dedicated PET is either unavailable or impractical.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14514343     DOI: 10.1530/eje.0.1490293

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  8 in total

1.  Clinical Usefulness of F-18 FDG PET/CT in Papillary Thyroid Cancer with Negative Radioiodine Scan and Elevated Thyroglobulin Level or Positive Anti-thyroglobulin Antibody.

Authors:  Su Jung Choi; Kyung Pyo Jung; Sun Seong Lee; Yun Soo Park; Seok Mo Lee; Sang Kyun Bae
Journal:  Nucl Med Mol Imaging       Date:  2015-10-22

2.  Could 18F-FDG-PET/CT avoid unnecessary thyroidectomies in patients with cytological diagnosis of follicular neoplasm?

Authors:  N Muñoz Pérez; J M Villar del Moral; M A Muros Fuentes; M López de la Torre; J I Arcelus Martínez; P Becerra Massare; D Esteva Martínez; M Cañadas Garre; E Coll Del Rey; P Bueno Laraño; J A Ferrón Orihuela
Journal:  Langenbecks Arch Surg       Date:  2013-04-28       Impact factor: 3.445

3.  Value of 111In-DOTA-lanreotide and 111In-DOTA-DPhe1-Tyr3-octreotide in differentiated thyroid cancer: results of in vitro binding studies and in vivo comparison with 18F-FDG PET.

Authors:  Margarida Rodrigues; Tatjana Traub-Weidinger; Maria Leimer; Shuren Li; Fritz Andreae; Peter Angelberger; Robert Dudczak; Irene Virgolini
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-05-21       Impact factor: 9.236

4.  ¹⁸F-FDG PET/CT changes therapy management in high-risk DTC after first radioiodine therapy.

Authors:  Sandra J Rosenbaum-Krumme; Rainer Görges; Andreas Bockisch; Ina Binse
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-06-21       Impact factor: 9.236

5.  The value of positron emission tomography in the surgical management of recurrent papillary thyroid carcinoma.

Authors:  Clive S Grant; Geoffrey B Thompson; David R Farley; Melanie L Richards; Brian P Mullan; Ian D Hay
Journal:  World J Surg       Date:  2008-05       Impact factor: 3.352

6.  Comparison of immunoradiometric assays for determination of thyroglobulin: a validation study.

Authors:  L A Tortajada-Genaro; M P Cózar; J L Moreno Frigols; C Romero de Avila
Journal:  J Clin Lab Anal       Date:  2007       Impact factor: 2.352

7.  Predicting 131I-avidity of metastases from differentiated thyroid cancer using 18F-FDG PET/CT in postoperative patients with elevated thyroglobulin.

Authors:  Min Liu; Lingxiao Cheng; Yuchen Jin; Maomei Ruan; Shiwei Sheng; Libo Chen
Journal:  Sci Rep       Date:  2018-03-12       Impact factor: 4.379

8.  Fluorodeoxyglucose-positron emission tomography scan-positive recurrent papillary thyroid cancer and the prognosis and implications for surgical management.

Authors:  Jennifer M J Schreinemakers; Menno R Vriens; Nuria Munoz-Perez; Marlon A Guerrero; Insoo Suh; Inne H M Borel Rinkes; Jessica Gosnell; Wen T Shen; Orlo H Clark; Quan-Yang Duh
Journal:  World J Surg Oncol       Date:  2012-09-17       Impact factor: 2.754

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.